{"id":515042,"date":"2021-07-20T08:33:58","date_gmt":"2021-07-20T12:33:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-2021-ascrs-american-society-of-cataract-and-refractive-surgery-annual-meeting\/"},"modified":"2021-07-20T08:33:58","modified_gmt":"2021-07-20T12:33:58","slug":"allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-2021-ascrs-american-society-of-cataract-and-refractive-surgery-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-2021-ascrs-american-society-of-cataract-and-refractive-surgery-annual-meeting\/","title":{"rendered":"Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting"},"content":{"rendered":"
\n

– Data presentations highlight Phase 3 GEMINI 1 trial results on the safety and efficacy of investigational AGN-190584 (pilocarpine 1.25%) as a potential novel treatment for presbyopia, a common and progressive eye condition that reduces the eye’s ability to focus on near objects<\/h2>\n

– New analyses of Phase 3 ARTEMIS studies provide further insights on the efficacy of DURYSTA\u2122 (bimatoprost intracameral implant) in patients with glaucoma<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NORTH CHICAGO, Ill.<\/span>, July 20, 2021<\/span> \/PRNewswire\/ —\u00a0Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) Annual Meeting being held July 23-27<\/span> in Las Vegas, NV.<\/span> Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an investigational presbyopia treatment, and updated analyses on DURYSTA\u2122 (bimatoprost intracameral implant), the first and only FDA-approved dissolvable implant to reduce eye pressure in people with open angle glaucoma or high eye pressure. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

“As a company, we remain committed to advancing care for difficult-to-treat eye conditions and diseases, such as presbyopia and glaucoma, that have a profound impact on daily life for millions of people,” said Michael R. Robinson<\/span>, M.D., vice president, global therapeutic area head, eye care, AbbVie. “Data presented at the 2021 ASCRS Annual Meeting will help us understand\u00a0the potential for AGN-190584 to be a first-of-its-kind treatment option for those living with presbyopia, as well as augment our knowledge of DURYSTA, which has changed how physicians can care for patients with glaucoma.”<\/p>\n

Researchers will present new data evaluating the efficacy, safety and tolerability of investigational AGN-190584 for the treatment of presbyopia, inclusive of full data results from the Phase 3 GEMINI 1 study. GEMINI 1 data, in combination with data from the GEMINI 2 study, formed the basis of the AGN-190584 New Drug Application (NDA) currently under review with the U.S. Food and Drug Administration, which the agency is expected to act on by the end of 2021.\u00a0<\/p>\n

Updated analyses from the Phase 3 ARTEMIS studies assessing the efficacy and duration of DURYSTA will also be presented. DURYSTA was approved by the FDA in March 2020<\/span> to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma (OAG) or high eye pressure (ocular hypertension, or OHT). Allergan has continued to collect data to further understand how DURYSTA can best be used to benefit patients living with glaucoma.<\/p>\n

A complete listing of the Allergan 2021 ASCRS Annual Meeting abstracts can be viewed at https:\/\/ascrs.confex.com\/ascrs\/21am\/meetingapp.cgi\/Home\/0<\/a>.<\/p>\n

Details about Allergan’s presentations are as follows:<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n \u00a0<\/span>\n <\/p>\n

\n
\n Abstract<\/b>
\n <\/span>\n <\/p>\n

\n Linked to ASCRS program<\/span>\n <\/p>\n<\/td>\n

\n

\n \u00a0<\/span>\n <\/p>\n

\n
\n Presentation Details<\/b>
\n <\/span>\n <\/p>\n

\n All Times PDT<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n \u00a0<\/span>\n <\/p>\n

\n
\n Glaucoma<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Duration of IOP Lowering with Bimatoprost Implant and Profile of the IOP-Lowering Response before Rescue in the Phase 3 Artemis Studies<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Minimally Invasive Glaucoma Surgery (MIGS) III<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 2:05 \u2013 2:10 p.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Bimatoprost Implant for IOP Lowering: Responder Rates Overall and in Subgroups By Previous Medication Count in the Phase 3 Artemis Studies<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Minimally Invasive Glaucoma Surgery (MIGS) III<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 2:10 \u2013 2:15 p.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Efficacy of Intracameral Bimatoprost Implant in Patients Stratified By Baseline IOP (\u226425 or >25 mmHg) in the Phase 3 Artemis Studies<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Minimally Invasive Glaucoma Surgery (MIGS) III<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 2:20 \u2013 2:25 p.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n \u00a0<\/span>\n <\/p>\n

\n
\n Presbyopia<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Gemini 1 Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 8:00 \u2013 8:05 a.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Evaluating Vision-Related Reading Ability with a De Novo PRO Instrument in a Phase 3 Study of AGN-190584 (Pilocarpine 1.25%) for Presbyopia<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 8:05 \u2013 8:10 a.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Assessing Presbyopia Impacts and Coping Behaviors with De Novo PRO Instruments in a Phase 3 Study of AGN-190584 (Pilocarpine 1.25%)<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 8:10 \u2013 8:15 a.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Gemini 1 Phase 3: AGN-190584 Provides Rapid Improvement of Distance Corrected Near Vision That Is Maintained in Participants with Presbyopia<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 8:15 \u2013 8:20 a.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Gemini 1 Phase 3: Safety and Efficacy of AGN-190584 in Participants with Presbyopia<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies<\/span>\n <\/p>\n

\n Sunday, July 25<\/span>\n <\/p>\n

\n 8:25 \u2013 8:30 a.m.<\/span>\n <\/p>\n

\n Room: MBCR \u2013 Level 2, Lagoon F<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

*ASCRS Disclaimer: All educational content of the ASCRS ASOA Annual Meeting is planned by its program committee, and ASCRS ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.<\/p>\n

\n About AGN-190584
<\/b>AGN-190584 is an investigational, novel optimized formulation of pilocarpine specifically designed for the treatment of presbyopia, as a topical, once-daily drop delivered by a proprietary vehicle. The primary mechanism of action is through dynamic pupil modulation, an effect in which the pupil is constricted to achieve an optimal pupil size range while maintaining pupillary response to different lighting conditions.\u00a0This allows for an increased depth of focus without compromising distance vision.<\/p>\n

\n DURYSTA<\/b>\u2122 Consumer Indications and Usage and Important Safety Information <\/b><\/p>\n

\n Approved Uses
<\/b>DURYSTA\u2122 (bimatoprost intracameral implant)\u00a0is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).\u00a0<\/p>\n

\n IMPORTANT SAFETY INFORMATION
<\/b>DURYSTA\u2122 should not be used if:<\/p>\n